Ceapro Inc.  

(Public, CVE:CZO)   Watch this stock  
Find more results for CZO
+0.040 (6.67%)
Dec 24 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.63 - 0.64
52 week 0.07 - 0.75
Open 0.63
Vol / Avg. 20,722.00/152,135.00
Mkt cap 39.31M
P/E 29.60
Div/yield     -
EPS 0.02
Shares 61.42M
Beta 0.92
Inst. own     -
Nov 14, 2014
Q3 2014 Ceapro Inc Earnings Release

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 28.22% 2.69%
Operating margin 29.90% 6.85%
EBITD margin - 12.90%
Return on average assets 38.64% 3.91%
Return on average equity 173.88% 136.26%
Employees 12 -
CDP Score - -


7824 51 Ave NW
+1-780-4214555 (Phone)
+1-780-4211320 (Fax)

Website links


Ceapro Inc. (Ceapro) is a biotechnology company. The Company is engaged in the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural and renewable resources. The Company�s products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, which are marketed to the personal care, cosmetic, medical, and animal health industries through our distribution partners and direct sales, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia, through agreements with Daisen Sangyo Co. Ltd.

Officers and directors

Gilles R. Gagnon President, Chief Executive Officer, Director
Age: 60
Branko Jankovic Chief Financial Officer, Corporate Secretary
Glenn R. Rourke Independent Chairman of the Board
William W. Li M.D. Director
Age: 49
Donald J. Oborowsky Independent Director
John Zupancic Independent Director